Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.74 |
| ▸ | NPC1 | O15118 | 2/20 | 0.74 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981608 | 0.88 | SMN1; SMN2 (0.57) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL4983996 | 0.87 | RAB9A (0.56) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL4975779 | 0.86 | DRD4 (0.59) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL24011436 | 0.86 | SMN1; SMN2 (0.63) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL4984077 | 0.85 | NPC1 (0.55) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL4977767 | 0.85 | MCHR1 (0.65) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL24011481 | 0.85 | NPC1 (0.68) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL4978994 | 0.85 | SMN1; SMN2 (0.72) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL14263119 | 0.84 | RAB9A (0.54) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 | |
| SCHEMBL3653016 | 0.84 | HTR2A (0.62) | RAB9ASMN1; SMN2NPC1MCHR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | ASTRAZENECA AB (SE) | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064706-A1 | Piperidine Derivatives as Histamine H3 Receptor Ligands | HRH3, HRH1, HRH4 | RAB9A 1386/4885SMN1; SMN2 4046/4885NPC1 4132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.